Papapit Tuchinda, Kanokvalai Kulthanan, Sakunee Khankham, Kowit Jongjarearnprasert, Naruemon Dhana
Abstract
Background: Previous studies have shown that calcium channel blockers can cause cutaneous
adverse reactions; however, the amounts of data collected are limited. Recently, there have been
new drugs available for which only a few reports have been published with regard to cutaneous
adverse reactions.
Objective: The purpose of our study was to estimate the rate and to study clinical patterns of
cutaneous adverse drug reactions to calcium channel blockers.
Methods: Medical records of patients who had cutaneous adverse reactions to calcium channel
blockers between January 2004 and December 2010, at the Adverse Drug Reaction Center of
Siriraj hospital, Mahidol University, Bangkok, Thailand were reviewed.
Results: From 996,583 prescriptions of calcium channel blockers, forty six patients developed
cutaneous adverse effects. Diltiazem was the drug that showed the highest rate of cutaneous
reactions per million prescriptions. Maculopapular rash was the most common
dermatologic manifestation (41.7%), followed by ankle/pedal edema (18.8%). Three patients
(6.2%) developed Stevens-Johnson syndrome due to amlodipine and 1 patient (2.1%) developed
toxic epidermal necrolysis due to manidipine.
Four patients (8.7%) had renal or cardiovascular involvement.
Conclusions: It is important to keep in mind that some patients may develop cutaneous adverse
reactions, including severe reactions, from calcium channel blockers.
Full Text: PDF
No comments:
Post a Comment